Zoetis (NYSE:ZTS) Price Target Lowered to $238.00 at Morgan Stanley

Zoetis (NYSE:ZTS) had its price objective dropped by investment analysts at Morgan Stanley from $243.00 to $238.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 50.93% from the stock’s current price.

A number of other analysts have also commented on ZTS. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Piper Sandler cut their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Finally, UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $213.50.

Zoetis Trading Down 4.4 %

Shares of NYSE:ZTS traded down $7.24 during trading on Friday, hitting $157.69. 1,536,488 shares of the company’s stock were exchanged, compared to its average volume of 2,906,391. The firm has a market cap of $71.15 billion, a P/E ratio of 29.72, a PEG ratio of 2.77 and a beta of 0.90. The firm has a 50-day moving average price of $168.89 and a two-hundred day moving average price of $178.98. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Equities analysts predict that Zoetis will post 5.9 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Institutional Trading of Zoetis

Hedge funds have recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. increased its stake in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Zoetis during the 3rd quarter valued at $31,000. First Personal Financial Services bought a new stake in Zoetis during the 3rd quarter valued at $33,000. Finally, Capital Performance Advisors LLP bought a new stake in Zoetis during the 3rd quarter valued at $33,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.